Winston Pharmaceuticals (Winston Pharmaceuticals) EBITDA Margin % : -144.79% (As of Mar. 2010)

View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Winston Pharmaceuticals's EBITDA for the three months ended in Mar. 2010 was $-0.46 Mil. Winston Pharmaceuticals's Revenue for the three months ended in Mar. 2010 was $0.32 Mil. Therefore, Winston Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2010 was -144.79%.

Winston Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Winston Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals EBITDA Margin % Chart

Winston Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Dec08

Dec09

EBITDA Margin %

-1,153.64

-195.84

Winston Pharmaceuticals Quarterly Data
	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10
EBITDA Margin %	Get a 7-Day Free Trial														-231.18	-187.67	-199.72	-165.19	-144.79

Competitive Comparison of Winston Pharmaceuticals's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Winston Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Winston Pharmaceuticals's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Winston Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Winston Pharmaceuticals's EBITDA Margin % falls into.

Winston Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Winston Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2009 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2009 )	/	Revenue (A: Dec. 2009 )
	=	-2.732	/	1.395
	=	-195.84 %

Winston Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2010 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2010 )	/	Revenue (Q: Mar. 2010 )
	=	-0.459	/	0.317
	=	-144.79 %

Winston Pharmaceuticals (GREY:WPHM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Winston Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061

Website

http://www.winstonlabs.com

Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser	10 percent owner	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver	director, officer: Vice President	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg	director, officer: Chief Financial Officer	2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel	10 percent owner	4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines